![]() |
Name |
Altenuene
|
Molecular Formula | C15H16O6 | |
IUPAC Name* |
(2S,3S,4aS)-2,3,7-trihydroxy-9-methoxy-4a-methyl-3,4-dihydro-2H-benzo[c]chromen-6-one
|
|
SMILES |
C[C@]12C[C@@H]([C@H](C=C1C3=C(C(=CC(=C3)OC)O)C(=O)O2)O)O
|
|
InChI |
InChI=1S/C15H16O6/c1-15-6-12(18)10(16)5-9(15)8-3-7(20-2)4-11(17)13(8)14(19)21-15/h3-5,10,12,16-18H,6H2,1-2H3/t10-,12-,15-/m0/s1
|
|
InChIKey |
MMHTXEATDNFMMY-WBIUFABUSA-N
|
|
Synonyms |
Altenuene; 29752-43-0; (2S,3S,4aS)-2,3,7-trihydroxy-9-methoxy-4a-methyl-3,4-dihydro-2H-benzo[c]chromen-6-one; BRN 4153870; CCRIS 8303; 5-18-05-00113 (Beilstein Handbook Reference); CHEMBL482228; MEGxm0_000136; ACon0_001041; ACon1_002175; DTXSID60891799; ZINC4533847; NCGC00179755-01; NCGC00179755-02; 6H-Dibenzo(b,d)pyran-6-one, 2,3,4,4a-tetrahydro-2,3,7-trihydroxy-9-methoxy-4a-methyl-, (2-alpha,3-beta,4a-beta)-(+-)-; BRD-K26184114-001-01-8; Q63409701; (2S,3S,4aS)-2,3,7-trihydroxy-9-methoxy-4a-methyl-4,4a-dihydro-2H-benzo[c]chromen-6(3H)-one; 2,3,4,4a-Tetrahydro-2alpha,3beta,7-trihydroxy-9-methoxy-4abeta-methyl-6H-dibenzo[b,d]pyran-6-one; NCGC00179755-02_C15H16O6_(2S,3S,4aS)-2,3,7-Trihydroxy-9-methoxy-4a-methyl-2,3,4,4a-tetrahydro-6H-benzo[c]chromen-6-one
|
|
CAS | 29752-43-0 | |
PubChem CID | 34687 | |
ChEMBL ID | CHEMBL482228 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 292.28 | ALogp: | 0.7 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 96.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 21 | QED Weighted: | 0.674 |
Caco-2 Permeability: | -4.736 | MDCK Permeability: | 0.00000677 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.099 |
Human Intestinal Absorption (HIA): | 0.057 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.039 |
Blood-Brain-Barrier Penetration (BBB): | 0.462 | Plasma Protein Binding (PPB): | 68.57% |
Volume Distribution (VD): | 0.304 | Fu: | 42.93% |
CYP1A2-inhibitor: | 0.026 | CYP1A2-substrate: | 0.801 |
CYP2C19-inhibitor: | 0.036 | CYP2C19-substrate: | 0.846 |
CYP2C9-inhibitor: | 0.041 | CYP2C9-substrate: | 0.446 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.283 |
CYP3A4-inhibitor: | 0.102 | CYP3A4-substrate: | 0.37 |
Clearance (CL): | 6.767 | Half-life (T1/2): | 0.73 |
hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.16 |
Drug-inuced Liver Injury (DILI): | 0.228 | AMES Toxicity: | 0.251 |
Rat Oral Acute Toxicity: | 0.321 | Maximum Recommended Daily Dose: | 0.866 |
Skin Sensitization: | 0.466 | Carcinogencity: | 0.046 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.119 |
Respiratory Toxicity: | 0.893 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000971 | ![]() |
1.000 | D07MGA | ![]() |
0.297 | ||
ENC004851 | ![]() |
1.000 | D0J4IX | ![]() |
0.240 | ||
ENC004819 | ![]() |
1.000 | D0P1FO | ![]() |
0.235 | ||
ENC006131 | ![]() |
1.000 | D0I9HF | ![]() |
0.232 | ||
ENC006132 | ![]() |
1.000 | D04UTT | ![]() |
0.227 | ||
ENC006071 | ![]() |
0.773 | D06GCK | ![]() |
0.223 | ||
ENC003769 | ![]() |
0.718 | D01XWG | ![]() |
0.221 | ||
ENC003974 | ![]() |
0.718 | D0AZ8C | ![]() |
0.220 | ||
ENC003686 | ![]() |
0.718 | D0C1SF | ![]() |
0.220 | ||
ENC004850 | ![]() |
0.718 | D08CCE | ![]() |
0.219 |